Sarah E. Servattalab
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sarah E. Servattalab has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Racquel A. Bitar
UMASS Chan Medical School Worcester Massachusetts USA
3 shared publications Yasin Damji
Harvard Medical School Boston Massachusetts USA
3 shared publications- Marilyn G. Liang
Vascular Anomalies Center Boston Children's Hospital Boston Massachusetts USA
2 shared publications Pierre-Olivier Grenier
Dermatology Section, Division of Immunology, Boston Children's Hospital, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts
2 shared publicationsPierre‐Olivier Grenier
Division of Dermatology Boston Children's Hospital Boston Massachusetts USA
2 shared publications- Sarah Lee
Harvard Medical School Boston Massachusetts USA
2 shared publications
Latest Publications
- 4 October 2026
- Published by Wiley in Pediatric Dermatology
Expanding Access to Care: Implementation of a Pediatric and Young Adult Laser Hair Removal Program for Hidradenitis Suppurativa
Laser hair removal (LHR) is an effective adjunctive therapy for hidradenitis suppurativa (HS), but access is often limited by inconsistent insurance coverage. A retrospective review was conducted of 21 pediatric and young adult patients enrolled in an LHR program for HS at a tertiary children's hospital. Among patients receiving two or more sessions ( n = 20), 86% demonstrated visible hair thinning or reduced hair regrowth on examination, and 81% self‐reported decreased flare severity or frequency, with no adverse events observed. All treatments were ultimately covered by insurance through a standardized prior authorization process, supporting the feasibility of expanding access to LHR for pediatric and young adult patients with HS.
- 4 October 2026
- Published by Wiley in Pediatric Dermatology
Expanding Access to Care: Implementation of a Pediatric and Young Adult Laser Hair Removal Program for Hidradenitis Suppurativa
Laser hair removal (LHR) is an effective adjunctive therapy for hidradenitis suppurativa (HS), but access is often limited by inconsistent insurance coverage. A retrospective review was conducted of 21 pediatric and young adult patients enrolled in an LHR program for HS at a tertiary children's hospital. Among patients receiving two or more sessions ( n = 20), 86% demonstrated visible hair thinning or reduced hair regrowth on examination, and 81% self‐reported decreased flare severity or frequency, with no adverse events observed. All treatments were ultimately covered by insurance through a standardized prior authorization process, supporting the feasibility of expanding access to LHR for pediatric and young adult patients with HS.
- 18 August 2026
- Published by Wiley in Pediatric Dermatology
Hepatitis B Immunity in Children on Immunomodulators: Implications From a Pediatric Dermatology Cohort and Review of the Literature
Background/Objectives: This study aims to determine the level of hepatitis B virus (HBV) immunity in patients who had HBV serologic testing prior to starting immunomodulatory medication for dermatologic conditions at a single institution and to review evidence on waning immunity, serologic interpretation, and revaccination. Methods: We performed a retrospective chart review of pediatric and young adult patients initiated on immunomodulatory therapy for dermatologic conditions who had HBV serologic testing prior to initiation. A focused literature review was conducted on durability of HBV immunity, HBV serologies in the context of immunomodulatory medications, and revaccination recommendations. Results: In this cohort of 23 children, roughly 40% lacked HBV serologic immunity. Prior studies demonstrated that antibody‐mediated protection is heterogeneous and anti‐HBs titers decline over time. Existing guidelines are largely derived from adult populations. Evidence regarding revaccination strategies is mixed. Notably, absence of detectable anti‐HBs antibodies does not always equate to loss of immune memory or susceptibility to infection. Conclusions: Anti‐HBs titers are variable and wane over time. Experts agree that patients should receive all recommended vaccinations before starting immunomodulatory therapy and be screened for HBV beforehand, based on adult guidelines. It is uncertain how well these recommendations apply to children, who generally have lower HBV risk and prevalence. Guidance is needed on how to manage pediatric patients without serologic evidence of HBV immunity before beginning biologic treatments.
- 18 August 2026
- Published by Wiley in Pediatric Dermatology
Hepatitis B Immunity in Children on Immunomodulators: Implications From a Pediatric Dermatology Cohort and Review of the Literature
Background/Objectives: This study aims to determine the level of hepatitis B virus (HBV) immunity in patients who had HBV serologic testing prior to starting immunomodulatory medication for dermatologic conditions at a single institution and to review evidence on waning immunity, serologic interpretation, and revaccination. Methods: We performed a retrospective chart review of pediatric and young adult patients initiated on immunomodulatory therapy for dermatologic conditions who had HBV serologic testing prior to initiation. A focused literature review was conducted on durability of HBV immunity, HBV serologies in the context of immunomodulatory medications, and revaccination recommendations. Results: In this cohort of 23 children, roughly 40% lacked HBV serologic immunity. Prior studies demonstrated that antibody‐mediated protection is heterogeneous and anti‐HBs titers decline over time. Existing guidelines are largely derived from adult populations. Evidence regarding revaccination strategies is mixed. Notably, absence of detectable anti‐HBs antibodies does not always equate to loss of immune memory or susceptibility to infection. Conclusions: Anti‐HBs titers are variable and wane over time. Experts agree that patients should receive all recommended vaccinations before starting immunomodulatory therapy and be screened for HBV beforehand, based on adult guidelines. It is uncertain how well these recommendations apply to children, who generally have lower HBV risk and prevalence. Guidance is needed on how to manage pediatric patients without serologic evidence of HBV immunity before beginning biologic treatments.
- 8 July 2026
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 95 (5) , 1461-1463
Disparities in care of infantile hemangiomas: A retrospective cohort study measuring the impact of area deprivation, race, and ethnicity
- 8 July 2026
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 95 (5) , 1461-1463
Disparities in care of infantile hemangiomas: A retrospective cohort study measuring the impact of area deprivation, race, and ethnicity
- 18 February 2026
- Published by Wiley in Pediatric Dermatology
- Vol. 43 (3) , 630-634
Leg Length Discrepancy in Patients With Lower Extremity Cutis Marmorata Telangiectatica Congenita: A Multicenter Retrospective Study
Objectives: To assess the frequency of leg length discrepancy (LLD) in patients with lower extremity cutis marmorata telangiectatica congenita (CMTC), describe associated findings, and characterize LLD management. Methods: We conducted a retrospective chart review of patients diagnosed with lower extremity CMTC by dermatology and evaluated by orthopedics at Boston Children's Hospital and Children's Hospital of Philadelphia from 1997 to 2024. LLD was assessed by orthopedic examination and/or radiographic imaging. Major LLD was defined as ≥ 2 cm at any age, or between 1 and 2 cm in children 4 years old or younger. Mild LLD was defined as < 2 cm, except when ≥ 1 cm was present by age 4. Kaplan–Meier analysis estimated the probability of developing major LLD by age 15. Results: Twenty‐eight patients with lower extremity CMTC were included. LLD was identified in 12 of 28 patients (43%), including 8 confirmed radiographically and 4 diagnosed by clinical assessment alone. Two (7%) were classified as major and 10 (36%) as mild. Limb hypoplasia occurred in 18 of 28 patients (64%). Kaplan–Meier analysis estimated a 7.1% cumulative risk of major LLD by age 15. Three of 12 patients (25%) with LLD were prescribed shoe lifts. Conclusion: LLD is common among patients with lower extremity CMTC. Early orthopedic assessment may facilitate timely intervention.
- 18 February 2026
- Published by Wiley in Pediatric Dermatology
- Vol. 43 (3) , 630-634
Leg Length Discrepancy in Patients With Lower Extremity Cutis Marmorata Telangiectatica Congenita: A Multicenter Retrospective Study
Objectives: To assess the frequency of leg length discrepancy (LLD) in patients with lower extremity cutis marmorata telangiectatica congenita (CMTC), describe associated findings, and characterize LLD management. Methods: We conducted a retrospective chart review of patients diagnosed with lower extremity CMTC by dermatology and evaluated by orthopedics at Boston Children's Hospital and Children's Hospital of Philadelphia from 1997 to 2024. LLD was assessed by orthopedic examination and/or radiographic imaging. Major LLD was defined as ≥ 2 cm at any age, or between 1 and 2 cm in children 4 years old or younger. Mild LLD was defined as < 2 cm, except when ≥ 1 cm was present by age 4. Kaplan–Meier analysis estimated the probability of developing major LLD by age 15. Results: Twenty‐eight patients with lower extremity CMTC were included. LLD was identified in 12 of 28 patients (43%), including 8 confirmed radiographically and 4 diagnosed by clinical assessment alone. Two (7%) were classified as major and 10 (36%) as mild. Limb hypoplasia occurred in 18 of 28 patients (64%). Kaplan–Meier analysis estimated a 7.1% cumulative risk of major LLD by age 15. Three of 12 patients (25%) with LLD were prescribed shoe lifts. Conclusion: LLD is common among patients with lower extremity CMTC. Early orthopedic assessment may facilitate timely intervention.
- 9 February 2026
- Published by Wiley in Pediatric Dermatology
- Vol. 43 (2) , 493-495
Successful Use of Adalimumab for Dissecting Cellulitis in a Pediatric Patient With Keratitis–Ichthyosis–Deafness ( KID ) Syndrome
Dissecting cellulitis of the scalp (DCS) is a chronic inflammatory condition characterized by painful, draining nodules and progressive, scarring alopecia. It is often refractory to treatment, and there are currently no FDA‐approved therapies. We present a case of a 15‐year‐old boy with keratitis–ichthyosis–deafness (KID) syndrome and DCS who experienced significant clinical response to treatment with adalimumab after failing multiple courses of oral antimicrobials, surgical interventions, intralesional corticosteroids, and topical therapies. Treatment with adalimumab led to reduction in drainage and pain and visible hair regrowth, highlighting its therapeutic potential in refractory, pediatric DCS including in the setting of syndromic skin disease.
- 9 February 2026
- Published by Wiley in Pediatric Dermatology
- Vol. 43 (2) , 493-495
Successful Use of Adalimumab for Dissecting Cellulitis in a Pediatric Patient With Keratitis–Ichthyosis–Deafness ( KID ) Syndrome
Dissecting cellulitis of the scalp (DCS) is a chronic inflammatory condition characterized by painful, draining nodules and progressive, scarring alopecia. It is often refractory to treatment, and there are currently no FDA‐approved therapies. We present a case of a 15‐year‐old boy with keratitis–ichthyosis–deafness (KID) syndrome and DCS who experienced significant clinical response to treatment with adalimumab after failing multiple courses of oral antimicrobials, surgical interventions, intralesional corticosteroids, and topical therapies. Treatment with adalimumab led to reduction in drainage and pain and visible hair regrowth, highlighting its therapeutic potential in refractory, pediatric DCS including in the setting of syndromic skin disease.
- Open Access
- 10 October 2025
- Published by Elsevier in JAAD Case Reports
- Vol. 66, 187-189
Atrophic, translucent plaque on the scalp of a newborn
- 10 October 2025
- Published by Elsevier in JAAD Case Reports
- Vol. 66, 187-189
Open AccessAtrophic, translucent plaque on the scalp of a newborn
- 17 July 2025
- Published by Wiley in Pediatric Dermatology
- Vol. 43 (1) , 113-115
Regional Infantile Hemangiomas Associated With Raynaud Phenomenon
Regional (segmental) infantile hemangioma (IH) can be associated with arterial anomalies, as seen in PHACE (posterior fossa anomalies, hemangioma, arterial anomalies, cardiac anomalies, and eye anomalies) and LUMBAR (lower body infantile hemangiomas, urogenital anomalies and ulceration, myelopathy, bony deformities, anorectal malformations and arterial anomalies, and rectal anomalies) associations. We describe two patients with a regional IH on the hand associated with Raynaud phenomenon. We hypothesize that Raynaud phenomenon in the setting of a regional IH may be due to post‐traumatic vasospastic response, arterial anomalies, cutaneous atrophy due to the IH, and/or changes in vasomotor regulation.
- 17 July 2025
- Published by Wiley in Pediatric Dermatology
- Vol. 43 (1) , 113-115
Regional Infantile Hemangiomas Associated With Raynaud Phenomenon
Regional (segmental) infantile hemangioma (IH) can be associated with arterial anomalies, as seen in PHACE (posterior fossa anomalies, hemangioma, arterial anomalies, cardiac anomalies, and eye anomalies) and LUMBAR (lower body infantile hemangiomas, urogenital anomalies and ulceration, myelopathy, bony deformities, anorectal malformations and arterial anomalies, and rectal anomalies) associations. We describe two patients with a regional IH on the hand associated with Raynaud phenomenon. We hypothesize that Raynaud phenomenon in the setting of a regional IH may be due to post‐traumatic vasospastic response, arterial anomalies, cutaneous atrophy due to the IH, and/or changes in vasomotor regulation.
- 29 May 2025
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 392 (20)
Tufted Angioma with Kasabach–Merritt Phenomenon
- 29 May 2025
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 392 (20)
Tufted Angioma with Kasabach–Merritt Phenomenon